A Phase 3 interventional study of Boostrix in Tetanus, Acellular Pertussis and Diphtheria, sponsored by GlaxoSmithKline. Completed at 20 sites in United States. Open to participants aged 19 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-06.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing boostrix in Tetanus — 2 open to participants now, 2 under way, none of them phase 3. Boostrix · Tetanus.
Among the 22 studies testing boostrix in Tetanus, this one is the 19th largest by enrollment, is one of 2 that started in 2013, is one of 12 in phase 3, and was the 14th registered.
318 studies on the registry are indexed under Tetanus; 29 are open to participants now.
Browse Tetanus studies →2 of the 22 studies testing boostrix in Tetanus are open now, in 1 country. Recruiting first, the newest first:
Changchun BCHT Biotechnology Co. · Sites in China
Ages 10+ · Healthy volunteers
Changchun BCHT Biotechnology Co.
Ages 10+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 16 Tetanus studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 19 Years to 30 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2013.
This study's enrollment of 165 is below the median of 418 across 280 interventional studies indexed under Tetanus.
Median enrollment 554 across the 22 interventional studies. Of the 20 that completed or were terminated, 14 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 22 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
106 studies in Tetanus by GlaxoSmithKline: none open now, 1 under way, 1 of them phase 3. Of 104 finished, 62 (60%) have results posted.
Among the 106 studies in Tetanus by GlaxoSmithKline, this one is the 83rd largest by enrollment of the 98 interventional ones that give a count, is one of 5 that started in 2013, is one of 60 in phase 3, and was the 85th registered.
GlaxoSmithKline’s Tetanus studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing boostrix in Tetanus, from their registry updates:
Among GlaxoSmithKline’s 106 in Tetanus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this follow-up study is to evaluate the persistence of antibodies against all the vaccine antigens 10 years after booster vaccination with either Tdap or Td, and also to assess immunogenicity and safety of another dose of Boostrix, administered in this study. This protocol posting deals with objectives and outcome measures of the extension phase. The objectives and outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00109330).
Subjects were previously vaccinated with either Boostrix or a control Td vaccine in study NCT00109330. Only subjects who were part of the primary study will be invited to participate in this study. All subjects will receive a single dose of Boostrix at Visit 1 (Day 0) and subjects will be observed till Visit 2 (Day 30) for safety in terms of solicited adverse events (during 4 days post vaccination), unsolicited adverse events (during 31 days post vaccination) and serious adverse event (during the trial period). A blood sample will be collected from all subjects before vaccination (Visit 1) and one month after vaccination (Visit 2) for antibodies estimation.
This summary has been updated following Protocol amendment 2 dated 03 October 2013. The protocol is being amended to facilitate enrolment by:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects of non- may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject
Exclusion Criteria:
Acute disease and/or fever at the time of enrolment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy male of female subjects, aged 19 to 30 years of age at the time of booster vaccination, who were randomized to the Lot A, Lot B or Lot C groups in study NCT00109330, received a second dose of Boostrix in this study.
Biological: Boostrix
Healthy male of female subjects, aged 19 to 30 years of age at the time of booster vaccination, who received Massachusetts Public Health Biologic Laboratories combined tetanus and diphtheria vaccine in study NCT00109330, received the first dose of Boostrix in this study.
Biological: Boostrix
Single dose intramuscular administration.
Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T).
A seroprotected subject was defined as a subject with anti-D/anti-T antibody concentrations above or equal (≥) to 0.1 IU/mL (international units per milliliter)
Time frame: At Month 1
Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Against Filamentous Hemagglutinin (Anti-FHA) and Against Pertactin (Anti-PRN).
Concentrations were expressed in geometric mean concentrations (GMCs).
Time frame: At Month 1
Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T).
A seroprotected subject was defined as a subject with anti-D/anti-T antibody concentrations above or equal (≥) to 0.1 IU/mL (international units per milliliter)
Time frame: At Month 0
Number of Subjects With Anti-D and Anti-T Concentrations Above the Cut-off.
The cut-off of the assay was ≥ 1.0 IU/mL.
Time frame: At Month 0 and Month 1
Anti-D and Anti-T Antibody Concentrations.
Concentrations were expressed as GMCs.
Time frame: At Month 0 and Month 1
Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Against Filamentous Hemagglutinin (Anti-FHA) and Against Pertactin (Anti-PRN).
Concentrations were expressed in geometric mean concentrations (GMCs).
Time frame: At Month 0
Number of Subjects With a Booster Response to Anti-D and Anti-T.
Booster response to anti-D and anti-T antigens was defined as: * for initially seronegative subjects with pre-booster antibody concentration below 0.1 IU/mL, an increase of at least four times 0.1 IU/mL one month after vaccination, * for initially seropositive subjects with pre-booster antibody concentration ≥ 0.1 IU/mL, an increase of at least four times the pre-booster antibody concentration one month after vaccination.
Time frame: At Month 1
Number of Subjects With a Booster Response to Anti-PT, Anti-FHA and Anti-PRN.
Booster response to pertussis antigens was defined as: * for initially seronegative subjects (pre-booster antibody concentration below the assay cut-off) with an increase of at least four times the assay cut-off one month after vaccination; * for initially seropositive subjects with anti-body concentration \< four times the assay cut-off with an increase of at least four times the pre-booster antibody concentration one month after vaccination; * for initially seropositive subjects with anti-body concentration ≥ four times the assay cut-off with an increase of at least two times the pre-booster antibody concentration one month after vaccination.
Time frame: At Month 1.
Number of Subjects With Solicited Local Symptoms.
The solicited local symptoms assessed were Pain, Redness and Swelling. Any = any solicited local symptom regardless of intensity.
Time frame: During the 4 days (Day 0 - 3) follow-up period after vaccination.
Number of Subjects With Solicited General Symptoms.
The solicited local symptoms assessed were Fatigue, Gastrointestinal, Headache and Fever. Any = any solicited general symptom regardless of intensity.
Time frame: During the 4 days (Day 0 - 3) follow-up period after vaccination.
Number of Subjects With Unsolicited Adverse Events (AEs).
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an adverse event (AE) reported in addition to those solicited during the clinical study. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.
Time frame: During the 31 days (Day 0 - 30) after vaccination.
Number of Subjects With Serious Adverse Events (SAEs).
SAEs assessed include medical occurrences that results in death, are life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.
Time frame: From Day 0 to 31 days post-vaccination.
| Milestone | Boostrix Group 1 | Boostrix Group 2 |
|---|---|---|
| Started | 37 | 128 |
| Completed | 36 | 124 |
| Not completed | 1 | 4 |
| Withdrew: Lost to follow-up | 1 | 4 |
A seroprotected subject was defined as a subject with anti-D/anti-T antibody concentrations above or equal (≥) to 0.1 IU/mL (international units per milliliter)
| Participants | Boostrix Group 1 | Boostrix Group 2 |
|---|---|---|
| Anti-D | 35 | 115 |
| Anti-T | 35 | 115 |
Concentrations were expressed in geometric mean concentrations (GMCs).
| IU/mL | Boostrix Group 1 | Boostrix Group 2 |
|---|---|---|
| anti-PT | 66.2 (50.8 to 86.2) | 87.3 (74.5 to 102.4) |
| anti-FHA | 336.2 (250.0 to 452.2) | 290.5 (252.5 to 334.2) |
| anti-PRN | 425.5 (281.9 to 642.3) | 463.3 (390.8 to 549.3) |
A seroprotected subject was defined as a subject with anti-D/anti-T antibody concentrations above or equal (≥) to 0.1 IU/mL (international units per milliliter)
| Participants | Boostrix Group 1 | Boostrix Group 2 |
|---|---|---|
| Anti-D | 35 | 115 |
| Anti-T | 35 | 115 |
The cut-off of the assay was ≥ 1.0 IU/mL.
| Participants | Boostrix Group 1 | Boostrix Group 2 |
|---|---|---|
| Anti-D at Month 0 | 23 | 70 |
| Anti-D at Month 1 | 34 | 115 |
| Anti-T at Month 0 | 27 | 86 |
| Anti-T at Month 1 | 35 | 115 |
Concentrations were expressed as GMCs.
| IU/mL | Boostrix Group 1 | Boostrix Group 2 |
|---|---|---|
| Anti-D at Month 0 | 1.6 (1.1 to 2.3) | 1.6 (1.3 to 2.1) |
| Anti-D at Month 1 | 6.8 (5.4 to 8.6) | 6.0 (5.3 to 6.9) |
| Anti-T at Month 0 | 1.8 (1.4 to 2.4) | 1.8 (1.5 to 2.2) |
| Anti-T at Month 1 | 9.9 (7.9 to 12.5) | 9.7 (8.5 to 11.0) |
Concentrations were expressed in geometric mean concentrations (GMCs).
| IU/mL | Boostrix Group 1 | Boostrix Group 2 |
|---|---|---|
| anti-PT | 5.3 (3.4 to 8.2) | 9.9 (8.1 to 12.2) |
| anti-FHA | 21.7 (13.4 to 35.4) | 36.9 (31.5 to 43.3) |
| anti-PRN | 27.8 (13.7 to 56.3) | 71.6 (56.7 to 90.6) |
Booster response to anti-D and anti-T antigens was defined as: * for initially seronegative subjects with pre-booster antibody concentration below 0.1 IU/mL, an increase of at least four times 0.1 IU/mL one month after vaccination, * for initially seropositive subjects with pre-booster antibody concentration ≥ 0.1 IU/mL, an increase of at least four times the pre-booster antibody concentration one month after vaccination.
| Participants | Boostrix Group 1 | Boostrix Group 2 |
|---|---|---|
| Anti-D | 14 | 47 |
| Anti-T | 21 | 64 |
Booster response to pertussis antigens was defined as: * for initially seronegative subjects (pre-booster antibody concentration below the assay cut-off) with an increase of at least four times the assay cut-off one month after vaccination; * for initially seropositive subjects with anti-body concentration \< four times the assay cut-off with an increase of at least four times the pre-booster antibody concentration one month after vaccination; * for initially seropositive subjects with anti-body concentration ≥ four times the assay cut-off with an increase of at least two times the pre-booster antibody concentration one month after vaccination.
| Participants | Boostrix Group 1 | Boostrix Group 2 |
|---|---|---|
| Anti-PT | 33 | 106 |
| Anti-FHA | 34 | 104 |
| Anti-PRN | 29 | 79 |
The solicited local symptoms assessed were Pain, Redness and Swelling. Any = any solicited local symptom regardless of intensity.
| Participants | Boostrix Group 1 | Boostrix Group 2 |
|---|---|---|
| Any Pain | 21 | 97 |
| Any Redness | 15 | 47 |
| Any Swelling | 7 | 30 |
The solicited local symptoms assessed were Fatigue, Gastrointestinal, Headache and Fever. Any = any solicited general symptom regardless of intensity.
| Participants | Boostrix Group 1 | Boostrix Group 2 |
|---|---|---|
| Any Fatigue | 8 | 38 |
| Any Gastrointestinal Symptoms | 1 | 11 |
| Any Headache | 8 | 40 |
| Any Fever | 1 | 3 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an adverse event (AE) reported in addition to those solicited during the clinical study. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.
| Participants | Boostrix Group 1 | Boostrix Group 2 |
|---|---|---|
| Number of Subjects With Unsolicited Adverse Events (AEs). | 10 | 33 |
SAEs assessed include medical occurrences that results in death, are life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.
| Participants | Boostrix Group 1 | Boostrix Group 2 |
|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs). | 0 | 0 |
Collected over Solicited local/general symptoms: during the 4-days (Days 0-3) post-vaccination period; Unsolicited AE(s): during the 31-day (Days 0-30) post-vaccination period; SAE(s): from Month 0 to Month 1.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Boostrix Group 1 | 0/37 (0%) | 0/37 (0%) | 30/37 (81.1%) |
| Boostrix Group 2 | 0/128 (0%) | 0/128 (0%) | 107/128 (83.6%) |
| Event | Boostrix Group 1 | Boostrix Group 2 |
|---|---|---|
| PainGeneral disorders | 21/37 | 97/128 |
| ErythemaSkin and subcutaneous tissue disorders | 15/37 | 47/128 |
| HeadacheNervous system disorders | 11/37 | 46/128 |
| FatigueGeneral disorders | 8/37 | 38/128 |
| SwellingGeneral disorders | 7/37 | 30/128 |
| Gastrointestinal disorderGastrointestinal disorders | 1/37 | 11/128 |
| DysmenorrhoeaReproductive system and breast disorders | 2/37 | 2/128 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/37 | 1/128 |
| Age, Continuous(Years) | Boostrix Group 1 | Boostrix Group 2 | Total |
|---|---|---|---|
| Mean | 23.3 ± 2.4 | 23.5 ± 2.1 | 23.5 ± 2.1 |
| Sex: Female, Male(Participants) | Boostrix Group 1 | Boostrix Group 2 | Total |
|---|---|---|---|
| Female | 18 | 57 | 75 |
| Male | 19 | 71 | 90 |
| Race/Ethnicity, Customized(Participants) | Boostrix Group 1 | Boostrix Group 2 | Total |
|---|---|---|---|
| Black | 1 | 6 | 7 |
| Oriental | 0 | 1 | 1 |
| Other | 5 | 7 | 12 |
| White/caucasian | 31 | 114 | 145 |
Ran from Jan 2013 to primary completion in Apr 2014, 14 months.
Results were first posted in Dec 2017, 3 years 8 months after primary completion. A results delay was requested in Apr 2015.
Of 55 industry-sponsored phase 3 interventional studies under Tetanus, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 21. This study's 14 months is above that.
Counting every sponsor, half of 56 studies reached it within 12 months; a quarter within 6 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Boostrix